Search result for antiviral
A new COVID therapy trial offers promising results: research
According to a study released on Wednesday, a single-injection antiviral treatment for newly infected COVID-19 patients lowered the likelihood of hospitalization by half in a large-scale clinical trial. The new medicine "showed remarkable benefits for both vaccinated and unvaccinated persons...
UK authorizes antiviral pill by Merck
Britain has granted conditional authorization to the first pill used for the treatment of COVID-19. UK is the first country to OK the treatment from Merck, even though the availability of the pill is yet not clear.
Highlights
- UK grants
HEALTH BENEFITS OF NIGHT JASMINE PLANT
Highlights –
- Health benefits of night jasmine plant.
- The entire plant is said to have medicinal benefits, night-jasmine’s leavesand flowers possess anti-inflammatory properties.
- Tea made from night-jasmine leaves and flowers co...
PHILIPPINES BEGIN CLINICAL TRIALS OF THE JAPANESE ANTI-FLU DRUG AVIGAN TO TREAT COVID-19
Highlights –
- Philippines begin clinical trials of the Japanese anti-flu drug Avigan to treat COVID-19.
- The trial is set for a period of 90 days at present.
- The clinical trials will be held in just four hospitals in Metro Manila at pr...
US: REMDESIVIR, THE ANTIVIRAL INTRAVENOUS DRUG THAT FIGHTS COVID, WILL RUN OUT IN JUNE 2020
Highlights:
- Remdesivir, the only proven drug to fight covid is running out in the US
- Gilead Sciences, the pharmaceutical company producing this drug has not given any clarity on the availability of the medicines stock for the summer.
- Till now this medicine ...
CALENDULA TEA IS A BLESSING
Highlights:
-Calendula tea has multiple health benefits.
-It is highly effective for a sore throat.
-It treats inflamed gums and blisters of the mouth.
Have you ever heard about Calendula tea? Well, it is actually a sure sh...
Peginterferon Lambda Combination Therapy for the Treatment of Chronic Hepatitis Delta Virus (HDV) launched by lambda.
BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and exploitation of targeted, first-in-class therapies for serious rare and ultra-rare diseases, these days proclaimed that a late-breaker speech has been granted for interim finish of treatment (Week 24) results of section 2 ele...